Acute Myelogenous Leukaemia

Marshall A Lichtman, University of Rochester Medical Center, Rochester, New York, USA

Published online: May 2010

DOI: 10.1002/9780470015902.a0002180.pub3

Acute myelogenous leukaemia is the result of a malignant transformation of a single primitive multipotential marrow haematopoietic cell, converting it to a leukaemic stem cell. This neoplastic transformation imparts a growth and survival advantage to the cell clone that emerges. Leukaemic cells fill the haematopoietic cords of marrow. The functional result of this alteration is to impair normal blood cell production in the marrow, leading to a profound decrease in normal red cells (anaemia), white cells (leucopaenia) and platelets or thrombocytes (thrombocytopaenia) in the blood. The disease is rapidly progressive, unless treated promptly. Therapy usually consists of at least two drugs, cytosine arabinoside and an anthracycline antibiotic (e.g. daunomycin). The response of the disease to treatment is dependent on several factors but the two most compelling are the age at diagnosis and the cytogenetic and genetic features of the cells with older age and unfavourable chromosomal karyotypes decreasing the proportion of long-term remissions.

Key Concepts:

  • Cancer of any type is the result of a series of gene mutations in a single tissue cell.
  • Acute myelogenous leukaemia, like all cancers, originates in a single tissue cell, in this case within haematopoietic tissue.
  • The incidence of acute myelogenous leukaemia can be increased by the inheritance of predisposition genes that are unapparent (nonsyndromic familial cases) or apparent as manifest by syndromic cases, such as Fanconi anaemia.
  • Leukaemic cells accumulate because they have a proliferative and survival advantage compared to normal cells.
  • It is estimated that approximately one trillion leukaemic cells are present at diagnosis.
  • Very small proportions of these cells are leukaemic stem cells, which sustain leukaemic haematopoiesis.
  • Acute myelogenous leukaemia stem cells have multipotential haematopoietic lineage potential. Thus, they can differentiate into leukaemic precursor cells of all haematopoietic lineages. The predominance of one or two leads to the phenotypic classification of acute myelogenous leukaemia (e.g. erythroid, monocytic, megakaryocytic and myelomonocytic).
  • The accumulation of leukaemic cells in the marrow secondarily suppresses normal blood cell development.
  • Chemotherapy is predicated on the coexistence of normal haematopoietic stem cells and leukaemic stem cells in the marrow.
  • Suppression of leukaemic cell accumulation by at least three logs by chemotherapy can, in many cases, result in the release of inhibition of normal stem cells and a return of normal haematopoiesis for a variable time.

Keywords: acute leukaemia; anaemia; chemotherapy; cytogenetics; leukopaenia; marrow; mutation; myelodysplasia; stem cell transplantation; thrombocytopaenia

 References
    Bullinger L, Krönke J, Schön C et al. (2010) Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia 24: 438–449.
    Casasnovas RO, Slimane FK, Garand R et al. (2003) Immunological classification of acute myeloblastic leukemia: relevance to patient outcomes. Leukemia 17: 515–527.
    Lichtman MA (2000) Myelodysplasia or myeloneoplasia: thoughts on the nosology of the clonal myeloid diseases. Blood Cells, Molecules, and Diseases 26: 572–581.
    other Lichtman MA (in press) Classification and clinical manifestations of the clonal myeloid diseases. In: Kaushansky K, Lichtman MA, Kipps TJ, Seligsohn U and Prchal JT (eds) William's Hematology, 8th edn, chap. 85, pp. 1211–1222. New York: McGraw-Hill.
    Lichtman MA and Rowe JM (2004) The relationship of patient age to the pathobiology of the clonal myeloid diseases. Seminars in Oncology 31: 185–197.
    Lichtman MA and Segel GB (2005) Uncommon phenotypes of acute myelogenous leukemia: basophilic, mast cell, eosinophilic, and myeloid dendritic cell subtypes: a review. Blood Cells, Molecules, and Diseases 35: 370–383.
    other Liesveld JL and Lichtman MA (in press) Acute myelogenous leukemia. In: Kaushansky K, LichtmanMA, Beutler E, Kipps TJ, Seligsohn U and Prchal JT (eds) William's Hematology, 8th edn, chap. 89, pp. 1047–1084. New York: McGraw-Hill.
    Lo-Coco F, Ammatuna E, Montesinos P and Sanz MA (2008) Acute promyelocytic leukemia: recent advances in diagnosis and management. Seminars in Oncology 35: 401–409.
    other Lowsky R and Negrin RS (in press) Allogeneic and autologous hematopoietic cell transplantation. In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U and Prchal JT (eds) William's Hematology, 8th edn, chap. 18, pp. 313–342. New York: McGraw-Hill.
    Mrózek K, Radmacher MD, Bloomfield CD and Marcucci G (2009) Molecular signatures in acute myeloid leukemia. Current Opinion in Hematology 16: 64–69.
    Rau R and Brown P (2009) Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematological Oncology 27: 171–181.
    Segel GB and Lichtman MA (2004) Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells, Molecules, and Diseases 32: 246–261.
    Smith SM, Le Beau MM, Huo D et al. (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102: 43–52.
    Stein E, McMahon B, Kwaan H et al. (2009) The coagulopathy of acute promyelocytic leukaemia revisited. Best Practice and Research Clinical Haematology 22: 153–163.
 Further Reading
    book Greer JP, Foerster J, Rodgers GM et al. (eds) (2009) Wintrobe's Clinical Hematology, 12th edn. Philadelphia: Lippincott Williams Wilkins.
    book Hoffman R, Benz EJ Jr, Shattil SJ et al. (eds) (2009) Hematology: Basic Principles and Practice, 5th edn. Philadelphia: Churchill-Livingston-Elsevier.
    other Kaushansky K, Lichtman MA, Beutler E et al. (eds) (in press) William's Hematology, 8th edn. New York: McGraw-Hill.

Related Sub-Topics:

Cells of the Immune System | Diagnostics, Therapeutics and Methods | Tumour Immunology | Cell Biology of Cancer
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Acute Myelogenous Leukaemia
 
How to Cite close
Lichtman, Marshall A(May 2010) Acute Myelogenous Leukaemia. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0002180.pub3]